H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of $70.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Neurogene’s potential despite its current undervaluation. The clinical results for NGN-401, particularly in the treatment of Rett syndrome, are compelling, showing deep and durable improvements across multiple domains without regression. This is evidenced by six out of eight patients surpassing the pivotal responder threshold, demonstrating more validated skill gains with fewer patients compared to competitors.
Kapoor notes that the market’s current valuation does not reflect these clinical successes, partly due to misinterpretations by some analysts rather than genuine investor skepticism. The recent selloff is seen as narrative noise, not a reflection of NGN-401’s clinical trajectory, which remains strong and promising. Furthermore, insights from a well-attended KOL call with Dr. David Lieberman emphasized the safety and long-term benefits of NGN-401, reinforcing its potential for adoption in irreversible gene therapies. This combination of clinical strength and market misalignment underpins Kapoor’s Buy rating and the 12-month price target of $70.